A Nigerian company is stepping up to tackle critical health challenges in Africa. Codix Bio Ltd has announced plans to produce millions of HIV and malaria test kits at its new manufacturing plant near Lagos, aiming to close the gap left by reduced international donor support.
Highlights:
- Codix Bio Ltd to manufacture millions of test kits locally.
- New plant located just outside Lagos.
- Move comes after funding cuts by U.S. agency USAID.
- Kits will serve Nigeria and other African countries.
Main Story:
In a bold move to strengthen healthcare across Africa, Nigerian pharmaceutical manufacturer Codix Bio Ltd will soon roll out mass production of HIV and malaria test kits. The company’s new facility, situated outside Lagos, is designed to supply both local and regional markets.
The initiative comes at a crucial time, as U.S. donor agency USAID has scaled back its support for HIV and malaria testing in the region. Codix Bio aims to ensure that communities continue to access affordable and reliable test kits despite the funding shortfall.
A company executive shared that the goal is not just to serve Nigeria but to meet demand in neighbouring countries, helping governments and health organisations sustain their fight against these deadly diseases.
The project is expected to create jobs, build capacity within Nigeria’s medical manufacturing sector, and reduce reliance on imported kits. It reflects a broader push for African solutions to African health challenges.
Could Codix Bio’s move spark a new era of health independence for Africa? Time will tell.
